Icatibant Sandoz

Icatibant, the active ingredient in Icatibant Sandoz, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage hereditary angioedema, a disorder driven by excessive bradykinin activity. - Acute hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces swelling during attacks. - Hereditary angioedema type I: provides quick symptom relief and improves airway safety. - Hereditary angioedema type II: alleviates abdominal pain and facial swelling associated with attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Injection site erythema: redness around the injection area. - Nausea: feeling of sickness or urge to vomit. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. - Flushing: transient redness of the skin.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of deeper skin layers, potentially affecting the airway. - Urticaria: hives or itchy welts. - Severe injection site reactions: necrosis or extensive swelling. - Thrombocytopenia: low platelet count observed rarely.

Before prescribing Icatibant, clinicians should consider several safety measures. - Confirm diagnosis: ensure the patient has hereditary angioedema with C1‑inhibitor deficiency. - Monitor hypersensitivity: watch for signs of anaphylaxis or severe allergic reactions. - Contraindication check: avoid use in patients with known hypersensitivity to icatibant or its excipients. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Injection technique: do not administer multiple injections at the same site to reduce local tissue damage. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or affect injection site tolerance.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and raise the risk of angioedema. - Estrogen‑containing contraceptives: can exacerbate hereditary angioedema symptoms. - Other bradykinin B2 antagonists: additive pharmacologic effect may increase adverse events.

Moderate Interactions (Monitor Closely): - C1‑inhibitor concentrate: concurrent use may complicate assessment of therapeutic response. - NSAIDs: may heighten the likelihood of local injection site reactions.